Sanara Medtech Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $35.34
- Today's High:
- $36.0993
- Open Price:
- $35.52
- 52W Low:
- $25.78
- 52W High:
- $50.18
- Prev. Close:
- $35.1
- Volume:
- 5887
Company Statistics
- Market Cap.:
- $316.93 million
- Book Value:
- 4.876
- Revenue TTM:
- $59.64 million
- Operating Margin TTM:
- -16.82%
- Gross Profit TTM:
- $39.48 million
- Profit Margin:
- -14.39%
- Return on Assets TTM:
- -11.97%
- Return on Equity TTM:
- -22.97%
Company Profile
Sanara Medtech Inc had its IPO on 2011-02-22 under the ticker symbol SMTI.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Sanara Medtech Inc has a staff strength of 101 employees.
Stock update
Shares of Sanara Medtech Inc opened at $35.52 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $35.34 - $36.1, and closed at $36.
This is a +2.56% increase from the previous day's closing price.
A total volume of 5,887 shares were traded at the close of the day’s session.
In the last one week, shares of Sanara Medtech Inc have slipped by -3.2%.
Sanara Medtech Inc's Key Ratios
Sanara Medtech Inc has a market cap of $316.93 million, indicating a price to book ratio of 6.4939 and a price to sales ratio of 8.1888.
In the last 12-months Sanara Medtech Inc’s revenue was $59.64 million with a gross profit of $39.48 million and an EBITDA of $-6817891. The EBITDA ratio measures Sanara Medtech Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sanara Medtech Inc’s operating margin was -16.82% while its return on assets stood at -11.97% with a return of equity of -22.97%.
In Q2, Sanara Medtech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 62.9%.
Sanara Medtech Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sanara Medtech Inc’s profitability.
Sanara Medtech Inc stock is trading at a EV to sales ratio of 7.6086 and a EV to EBITDA ratio of -25.0698. Its price to sales ratio in the trailing 12-months stood at 8.1888.
Sanara Medtech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $58.28 million
- Total Liabilities
- $9.88 million
- Operating Cash Flow
- $-12945.00
- Capital Expenditure
- $12945
- Dividend Payout Ratio
- 0%
Sanara Medtech Inc ended 2024 with $58.28 million in total assets and $0 in total liabilities. Its intangible assets were valued at $58.28 million while shareholder equity stood at $41.15 million.
Sanara Medtech Inc ended 2024 with $0 in deferred long-term liabilities, $9.88 million in other current liabilities, 8440.00 in common stock, $-26740930.00 in retained earnings and $3.60 million in goodwill. Its cash balance stood at $6.06 million and cash and short-term investments were $6.06 million. The company’s total short-term debt was $273,539 while long-term debt stood at $0.
Sanara Medtech Inc’s total current assets stands at $18.18 million while long-term investments were $3.08 million and short-term investments were $0. Its net receivables were $7.21 million compared to accounts payable of $1.02 million and inventory worth $4.42 million.
In 2024, Sanara Medtech Inc's operating cash flow was $-12945.00 while its capital expenditure stood at $12945.
Comparatively, Sanara Medtech Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $36
- 52-Week High
- $50.18
- 52-Week Low
- $25.78
- Analyst Target Price
- $59
Sanara Medtech Inc stock is currently trading at $36 per share. It touched a 52-week high of $50.18 and a 52-week low of $50.18. Analysts tracking the stock have a 12-month average target price of $59.
Its 50-day moving average was $40.04 and 200-day moving average was $40.79 The short ratio stood at 12.51 indicating a short percent outstanding of 0%.
Around 6214.9% of the company’s stock are held by insiders while 603.6% are held by institutions.
Frequently Asked Questions About Sanara Medtech Inc
Similar Industry Stocks (Medical Instruments & Supplies)
Most Active
Top Gainers
Top Losers
About
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.